Cerevel Therapeutics Holdings, Inc.
CERE · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $5,627 | $4,903 | $2,731 | $397 |
| Gross Profit | -$5,627 | -$4,903 | -$2,731 | -$397 |
| % Margin | – | – | – | – |
| R&D Expenses | $334,641 | $280,259 | $161,855 | $103,303 |
| G&A Expenses | $112,624 | $87,589 | $58,243 | $45,813 |
| SG&A Expenses | $112,624 | $87,589 | $58,243 | $45,813 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $6,878 | -$5,393 | $0 |
| Operating Expenses | $465,637 | $367,848 | $220,098 | $149,116 |
| Operating Income | -$447,265 | -$367,848 | -$220,098 | -$149,116 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $14,926 | $16,497 | -$5,236 | -$3,050 |
| Pre-Tax Income | -$432,339 | -$351,351 | -$225,334 | -$152,166 |
| Tax Expense | $503 | $160 | -$2,888 | -$24 |
| Net Income | -$432,842 | -$351,511 | -$222,446 | -$152,142 |
| % Margin | – | – | – | – |
| EPS | -2.67 | -2.32 | -1.63 | -1.29 |
| % Growth | -15.1% | -42.3% | -26.4% | – |
| EPS Diluted | -2.67 | -2.32 | -1.63 | -1.29 |
| Weighted Avg Shares Out | 162,056 | 151,266 | 136,577 | 118,181 |
| Weighted Avg Shares Out Dil | 162,056 | 151,266 | 136,577 | 118,181 |
| Supplemental Information | – | – | – | – |
| Interest Income | $43,865 | $9,619 | $157 | $224 |
| Interest Expense | $10,567 | $9,619 | $0 | $0 |
| Depreciation & Amortization | $5,627 | $4,903 | $2,731 | $397 |
| EBITDA | -$416,145 | -$336,829 | -$211,984 | -$148,719 |
| % Margin | – | – | – | – |